This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herrmann, T. Articles by Jung, G. Search for Related Content PubMed PubMed Citation Articles by Herrmann, T. Articles by Jung, G.

Construction of Optimized Bispecific Antibodies for Selective Activation of the Death Receptor CD95

¹ Department of Immunology, University of Tübingen, Tübingen, Germany and ² Tumor Immunology Program, Division of Immunogenetics, German Cancer Research Center, Heidelberg, Germany

Requests for reprints: Gundram Jung, Department of Immunology, University of Tübingen, Auf der Morgenstelle 15, D-72076 Tübingen, Germany. Phone: 49-7071-29-87621; Fax: 49-7071-29-5653; E-mail: gundram.jung{at}uni-tuebingen.de.

Key Words: bispecific antibodies • glioblastoma • CD95 • NG2 • Tenascin

We have previously reported that bispecific antibodies directed to different target antigens on lymphoma cells and to the death receptor CD95/Fas/Apo-1 selectively kill these cells, thus providing an attractive strategy for the selective stimulation of CD95 on the surface of tumor cells. Here, we further explore the general applicability of this approach under more stringent conditions using various bispecific antibodies directed to different target antigens on glioblastoma cells which express relatively low levels of CD95. We found that bispecific CD95 antibodies targeting the neuronal glial antigen-2 induce CD95-mediated apoptosis selectively in glioblastoma cells expressing this target antigen. A recombinant bispecific single-chain antibody was as effective as a chemically hybridized F(ab')₂ fragment with identical specificities. In contrast, a bispecific F(ab')₂ fragment binding to the epidermal growth factor receptor on the glioblastoma cells failed to induce apoptosis. This is most likely due to the exclusively unicellular binding of this particular fragment to target cells expressing both the epidermal growth factor receptor and CD95. If this type of binding in a cis configuration is favored by a particular bispecific antibody, rather than a bicellular binding in trans, effective cross-linking of CD95 does not occur and apoptosis is not induced. To facilitate bicellular binding in a trans configuration, we constructed a bispecific antibody directed to the extracellular matrix protein tenascin. As expected, this reagent was the most effective of all the antibodies tested. The presence of sensitizing reagents such as cycloheximide and various cytostatic drugs further enhanced antibody-mediated killing of the tumor cells. We believe that these results may point the way to a successful application of bispecific CD95 antibodies in experimental tumor therapy. [Cancer Res 2008;68(4):1221–7]

This article has been cited by other articles:

				H Schulze-Bergkamen, A Weinmann, M Moehler, J Siebler, and P R Galle Novel ways to sensitise gastrointestinal cancer to apoptosis Gut, July 1, 2009; 58(7): 1010 - 1024. [Abstract] [Full Text] [PDF]

				J. C. Symes, M. Kurin, N. E. Fleshner, and J. A. Medin Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel Mol. Cancer Ther., September 1, 2008; 7(9): 3018 - 3028. [Abstract] [Full Text] [PDF]